Aclarion, Inc. (ACONW) Financial Statements (2026 and earlier)

Company Profile

Business Address 8181 ARISTA PLACE
BROOMFIELD, CO 80021
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 8071 - Medical Laboratories (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments12,01611,34112,82614,7504541,312
Cash and cash equivalent12,01611,34112,82614,7504541,312
Receivables303221191817
Deferred costs      60
Other current assets 9999   
Other undisclosed current assets351432495388352508
Total current assets:12,39711,90513,44115,1578241,897
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization24136551
Intangible asset, including goodwill, after accumulated amortization1,2521,2821,3071,3171,2941,290
Intangible asset, excluding goodwill, after accumulated amortization1,2521,2821,3071,3171,2941,290
Total noncurrent assets:1,2761,2961,3141,3221,2991,291
TOTAL ASSETS:13,67213,20014,75516,4802,1233,188
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities333274282516532332
Accounts payable333274282516532332
Derivative instruments and hedges, liabilities0     
Other undisclosed current liabilities504425283183622347
Total current liabilities:8377005646991,153678
Noncurrent Liabilities
Total liabilities:8377005646991,153678
Equity
Equity, attributable to parent, including:12,83512,50114,19015,7819702,510
Common stock     0
Additional paid in capital71,33169,10769,09169,08052,23251,782
Accumulated deficit(58,496)(56,607)(54,901)(53,300)(51,262)(49,273)
Other undisclosed equity, attributable to parent 0000  
Total equity:12,83512,50114,19015,7819702,510
TOTAL LIABILITIES AND EQUITY:13,67213,20014,75516,4802,1233,188

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues181919191014
Cost of revenue(17)(15)(14)(23)(21)(21)
Gross profit:245(4)(10)(7)
Operating expenses(1,995)(1,835)(1,742)(1,487)(1,796)(1,289)
Operating loss:(1,993)(1,831)(1,737)(1,492)(1,806)(1,296)
Nonoperating income (expense)104125136(546)(183)(70)
Other nonoperating income (expense)(307)12513642(93)0
Loss from continuing operations:(1,889)(1,706)(1,601)(2,037)(1,990)(1,366)
Other undisclosed net income (loss)    (7)12(12)
Net loss:(1,889)(1,706)(1,601)(2,044)(1,977)(1,378)
Other undisclosed net income (loss) attributable to parent    7(12)12
Net loss attributable to parent:(1,889)(1,706)(1,601)(2,037)(1,990)(1,366)
Preferred stock dividends and other adjustments    (7)(48)(12)
Net loss available to common stockholders, diluted:(1,889)(1,706)(1,601)(2,044)(2,037)(1,378)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net loss:(1,889)(1,706)(1,601)(2,044)(1,977)(1,378)
Comprehensive loss, net of tax, attributable to parent:(1,889)(1,706)(1,601)(2,044)(1,977)(1,378)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: